Market revenue in 2023 | USD 159.8 million |
Market revenue in 2030 | USD 244.8 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.49% in 2023. Horizon Databook has segmented the UK central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure and support from government institutions & initiatives are among the key factors expected to propel the growth of the central lab market in the UK.
The UK Clinical Research Collaboration (UKCRC) provides a forum for its partner members to collaborate to drive advancements in clinical research, while the UK Research and Innovation (UKRI) promotes research initiatives and funding opportunities in this domain.
These institutions have propelled clinical development pertaining to the COVID-19 pandemic, thereby expanding the scope for conducting clinical trials in the UK. For instance, the RECOVERY trial for investigation of COVID-19 treatments recruited over 40,000 participants from more than 185 trial sites in the UK.
Horizon Databook provides a detailed overview of country-level data and insights on the UK central lab market , including forecasts for subscribers. This country databook contains high-level insights into UK central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account